MyFinsight
Home
Blog
About
Proceeds from issuance of
2032 convertible...
$525,000K
Inducement expense
$40,008K
Accrued expenses
$30,094K
(467.00%↑ Y/Y)
Proceeds from exercise of
stock options
$27,841K
(491.61%↑ Y/Y)
Proceeds from issuances
under the employee...
$2,356K
(53.29%↑ Y/Y)
Share based
compensation
$21,788K
(-1.59%↓ Y/Y)
Accounts receivable
-$6,642K
(-157.83%↓ Y/Y)
Depreciation and
amortization
$4,234K
(-84.21%↓ Y/Y)
Foreign currency
remeasurement impact
-$3,416K
(-257.78%↓ Y/Y)
Other current and
non-current liabilities
$2,947K
(93.25%↑ Y/Y)
Net cash provided by
financing activities
$187,517K
(3510.96%↑ Y/Y)
Net cash provided by
(used in) operating...
$58,071K
(256.06%↑ Y/Y)
Effect of exchange rate
changes on cash
$72K
(-97.12%↓ Y/Y)
Canceled cashflow
$367,680K
Canceled cashflow
$48,592K
Net increase in cash
and cash...
$39,373K
(136.92%↑ Y/Y)
Canceled cashflow
$206,287K
Repurchase of 2029
convertible senior notes...
$350,885K
Payment of debt issuance
costs
$16,270K
Payment of guaranteed
minimum royalty
$525K
(-50.00%↓ Y/Y)
Proceeds from the sale and
maturity of marketable...
$36,367K
(-72.97%↓ Y/Y)
Net loss from
continuing operations
-$34,797K
(35.54%↑ Y/Y)
Accounts payable
-$5,402K
(-3.43%↓ Y/Y)
Prepaid expenses and
other current and...
$3,075K
(-54.63%↓ Y/Y)
Inventory
$2,708K
(174.29%↑ Y/Y)
Other
$2,610K
(276.62%↑ Y/Y)
Net cash (used in)
provided by investing...
-$206,287K
(-547.09%↓ Y/Y)
Canceled cashflow
$36,367K
Purchase of marketable
debt securities
$221,583K
(244.23%↑ Y/Y)
Purchase of intangible
assets
$21,071K
(-11.73%↓ Y/Y)
Back
Back
Cash Flow
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)
source: myfinsight.com